Anteris Technologies Global/$AVR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Anteris Technologies Global
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
- Ticker
- $AVR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 174
- Headquarters
- Toowong, Australia
- Website
- anteristech.com
AVR Metrics
BasicAdvanced
$555M
-
-$1.62
-
-
Price and volume
Market cap
$555M
52-week high
$11.06
52-week low
$3.30
Average daily volume
1.6M
Financial strength
Current ratio
14.197
Quick ratio
14.02
Long term debt to equity
0.009
Total debt to equity
0.013
Interest coverage (TTM)
-580.51%
Profitability
EBITDA (TTM)
-104.496
Gross margin (TTM)
74.98%
Net profit margin (TTM)
-4,619.27%
Operating margin (TTM)
-4,738.36%
Effective tax rate (TTM)
-0.48%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-42.51%
Return on equity (TTM)
-74.65%
Valuation
Price to revenue (TTM)
162.428
Price to book
2.2
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-4.126
Free cash flow yield (TTM)
-24.24%
Free cash flow per share (TTM)
-1.379
Growth
Revenue change (TTM)
-9.56%
Earnings per share change (TTM)
-44.00%
3-year revenue growth (CAGR)
-9.18%
3-year earnings per share growth (CAGR)
-13.35%
What the Analysts think about AVR
Analyst ratings (Buy, Hold, Sell) for Anteris Technologies Global stock.
Analyst projections of the future price of Anteris Technologies Global stock.
Bulls say / Bears say
In 22 medium-annulus patients, DurAVR showed a mean pressure gradient of 6.17 mmHg and no moderate or severe valve leak, mismatch or valve-related deaths at 30 days. These are encouraging early results for the valve’s blood-flow performance. (Anteris Technologies Global Corp.)
German regulatory clearance lets Anteris begin recruiting at German centres for PARADIGM, adding to recruitment already underway in the US and parts of Europe. A broader site network could help the company execute its pivotal trial. (Anteris Technologies Global Corp., U.S. Securities and Exchange Commission)
Anteris had $260.9 million in cash, cash equivalents and restricted cash at the end of June 2026. Management said its current cash should cover operating needs for at least 12 months, supporting the company as it advances the trial. (U.S. Securities and Exchange Commission)
The latest positive readout covers just 22 patients at 30 days and reports no comparison with an approved valve. It therefore does not show whether DurAVR performs as well as, or better than, established options. (Anteris Technologies Global Corp., AInvest)
The business remains development-stage, with minimal sales and substantial losses while it funds clinical trials and manufacturing. It reported $20.8 million of operating cash outflow in the second quarter, so continued spending could weaken its financial position before commercial sales begin. (U.S. Securities and Exchange Commission)
DurAVR still needs successful pivotal-trial results and FDA premarket approval before it can be sold in the US; the company says there is no guarantee it will achieve either. Anteris also has a share-sale programme of up to $250 million, which could dilute existing holders if used to fund development. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
AVR Financial Performance
Revenues and expenses
AVR Earnings Performance
Company profitability
Upcoming events
No upcoming events
AVR News
AllArticlesVideos
Funds containing AVR
Fund name | Fund size | $AVR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.